1-4 of 4
Michael Robbins, BS
Close
Sort by
Journal Articles

Effects of Elotuzumab on Soluble SLAMF7 Levels in Multiple Myeloma

Jennifer Postelnek, BA, James Sheridan, Steve Keller, Tatiana Pazina, MS, BS, Jennifer Sheng, Valerie Poulart, Michael Robbins, BS
Journal: Blood
Blood (2015) 126 (23): 2964.
https://doi.org/10.1182/blood.V126.23.2964.2964
Published: 2015
Journal Articles

Targeting Mechanisms for Natural Killer Cell Dysfunction in Patients with Multiple Myeloma

Misty Jenkins, PhD, Rachael Canfield, BSc, Michael Robbins, BS, David S. Ritchie, MDPhD, Joe Trapani, Paul Neeson, BSc, PhD
Journal: Blood
Blood (2015) 126 (23): 4237.
https://doi.org/10.1182/blood.V126.23.4237.4237
Published: 2015
Journal Articles

Effects of IL-21, KIR Blockade, and CD137 Agonism on the Non-Clinical Activity of Elotuzumab

Michael Robbins, BS, Maria Jure-Kunkel, DVM, PhD, Gennaro Dito, BS, Pascale Andre, PhD, Hui-fen Zhang, PhD, Natalie Bezman, PhD, Robert F Graziano, PhD
Journal: Blood
Blood (2014) 124 (21): 4717.
https://doi.org/10.1182/blood.V124.21.4717.4717
Published: 2014
Journal Articles

Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma

Siobhan Glavey, MD, Michaela Reagan, PhD, Salomon Manier, MD, Michele Moschetta, MD, Yawara Kawano, MDPhD, Antonio Sacco, BS, Aldo M Roccaro, MD PhD, Michael Robbins, BS, Irene M. Ghobrial, MD
Journal: Blood
Blood (2014) 124 (21): 3431.
https://doi.org/10.1182/blood.V124.21.3431.3431
Published: 2014